Gofen & Glossberg LLC IL boosted its stake in Becton Dickinson and Co (NYSE:BDX) by 12.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,153 shares of the medical instruments supplier’s stock after acquiring an additional 4,359 shares during the period. Gofen & Glossberg LLC IL’s holdings in Becton Dickinson and were worth $9,619,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Sustainable Growth Advisers LP purchased a new stake in Becton Dickinson and in the 1st quarter valued at approximately $166,282,000. Rockefeller Capital Management L.P. purchased a new stake in Becton Dickinson and in the 1st quarter valued at approximately $87,368,000. The Manufacturers Life Insurance Company boosted its holdings in Becton Dickinson and by 61.4% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,033,592 shares of the medical instruments supplier’s stock valued at $223,979,000 after purchasing an additional 393,135 shares in the last quarter. CI Investments Inc. purchased a new stake in Becton Dickinson and in the 1st quarter valued at approximately $75,520,000. Finally, TIAA CREF Investment Management LLC boosted its holdings in Becton Dickinson and by 38.4% in the 4th quarter. TIAA CREF Investment Management LLC now owns 951,936 shares of the medical instruments supplier’s stock valued at $203,771,000 after purchasing an additional 264,325 shares in the last quarter. Hedge funds and other institutional investors own 84.08% of the company’s stock.
In related news, EVP Nabil Shabshab sold 10,209 shares of the company’s stock in a transaction that occurred on Friday, May 11th. The stock was sold at an average price of $226.10, for a total value of $2,308,254.90. Following the sale, the executive vice president now owns 12,476 shares of the company’s stock, valued at approximately $2,820,823.60. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Alexandre Conroy sold 20,128 shares of the company’s stock in a transaction that occurred on Monday, May 21st. The shares were sold at an average price of $228.74, for a total value of $4,604,078.72. Following the completion of the sale, the insider now directly owns 35,583 shares in the company, valued at approximately $8,139,255.42. The disclosure for this sale can be found here. 1.00% of the stock is currently owned by corporate insiders.
Shares of NYSE:BDX opened at $244.63 on Thursday. The company has a market cap of $65.34 billion, a PE ratio of 24.48, a PEG ratio of 1.70 and a beta of 1.12. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.12 and a current ratio of 1.70. Becton Dickinson and Co has a 12 month low of $191.53 and a 12 month high of $248.39.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.63 by $0.02. The business had revenue of $4.22 billion for the quarter, compared to analyst estimates of $4.12 billion. Becton Dickinson and had a positive return on equity of 14.27% and a negative net margin of 0.46%. The company’s quarterly revenue was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.30 EPS. analysts expect that Becton Dickinson and Co will post 10.99 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, June 29th. Stockholders of record on Friday, June 8th were paid a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.23%. The ex-dividend date was Thursday, June 7th. Becton Dickinson and’s dividend payout ratio (DPR) is 31.65%.
BDX has been the topic of a number of analyst reports. Citigroup raised Becton Dickinson and from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $237.00 to $251.00 in a report on Tuesday, April 10th. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. Finally, JPMorgan Chase & Co. raised Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective on the stock in a report on Thursday, June 21st. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $240.88.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.